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ERBB2 expression has been found in 19 to 44% of ovarian carcinomas; however, its predictive value has not been demonstrated, and
trastuzumab has not found clinical application in ovarian cancer patients. We evaluated clinical significance of ERBB2 expression in
relation to TP53 accumulation in ovarian carcinoma patients treated with platinum-based regimens. Immunohistochemical analysis
with CB11 and a novel NCL-CBE356 antibody (against the internal and external domains of ERBB2, respectively) was performed on
233 tumours (FIGO stage IIB—IV); the US Food and Drug Administration-approved grading system with 0 to 3þ scale was used for
evaluation, and the results were analysed by the Cox and logistic regression models. In all, 42% of the tumours expressed (category
1þ,2þ or 3þ) either CB11 or CBE356 or both (CB11/CBE356 parameter). Associations between ERBB2 expression and clinical
factors were observed only if tumours with staining category 1þ were grouped together with tumours showing staining categories
2þ and 3þ. CB11/CBE356 parameter had a better predictive value than CB11 alone. CB11/CBE356 expression was negatively
associated with platinum sensitivity (PS) in the TP53( ) group (P¼0.022) and with disease-free survival (DFS) in the TP53(þ)
group (P¼0.009). Our results may suggest that trastuzumab should be given postoperatively to patients with TP53( )/ERBB2(þ)
ovarian carcinomas to enhance PS, and after completion of chemotherapy to patients with complete remission and TP53(þ)/
ERBB2(þ) carcinomas to extend DFS time (in total to 30.4% of all patients analysed). Thus, novel criteria for ovarian cancer patient
inclusion for clinical trials with trastuzumab should be considered and tested.
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ERBB2 (HER-2) is a transmembrane tyrosine kinase receptor
protein that belongs to the epidermal growth factor receptor family
(HER-1, HER-2, HER-3, HER-4) (Slamon et al, 1989; Baselga and
Albanell, 2001; Ross et al, 2003). The HER family participates
primarily in transduction of proliferation signals from various
ligands, and this process involves dimer formation between
different HER receptors. The presence of HER-2 in a heterodimer
results in more efficient stability and signalling (Baselga and
Albanell, 2001; Ross et al, 2003). Overexpression of HER-2 results
also in the formation of homodimers, which may be constitutively
active (Baselga and Albanell, 2001).
The expression of HER-2 is an established prognostic factor in
breast cancer. A monoclonal antibody against the external epitope
of HER-2, that is, trastuzumab, is used for therapy of breast cancer
patients whose tumours express high levels of HER-2, that is,
2þ and 3þ US Food and Drug Administration-approved
category (Press et al, 2002; Ross et al, 2003).
Some data from cell lines overexpressing ERBB2 showed that
therapy with trastuzumab and cisplatin had a synergistic effect
(Hancock et al, 1991). This could create a possibility of more
efficient therapy in ovarian cancer patients. However, despite
relatively frequent ERBB2 overexpression or gene amplification in
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yovarian carcinomas (range 19–44%, Table 1), its clinical
importance has been barely demonstrated (Berchuck et al, 1990;
Kacinski et al, 1992; Rubin et al, 1993; Scambia et al, 1993; Meden
et al, 1994; Fajac et al, 1995; Felip et al, 1995; Van der Zee et al,
1995; Tanner et al, 1996; Meden et al, 1998; Hengstler et al, 1999;
Ferrandina et al, 2002). Only Berchuck et al (1990) and Felip et al
(1995) observed lower frequency of complete remission (CR) in
ERBB2-overexpressing tumours; however, they have not confirmed
this by multivariate analysis. To date, trastuzumab has not found
clinical application in ovarian cancer patients, neither combined
with chemotherapy nor as monotherapy (Bookman et al, 2003).
We think that lack of clinical associations of ERBB2 over-
expression in ovarian cancer studies may be due to (1) small group
sizes (Table 1); (2) no regard to TP53 status and (3) overly
restrictive criteria of ERBB2 overexpression.
We have recently shown that TP53 status may influence clinical
importance of some molecular and clinical factors in ovarian
carcinoma patients (Kupryjanczyk et al, 2003, 2004). The same
may be true with regard to ERBB2. Some experimental studies have
shown that wild-type TP53 protein limits or abrogates biological
effects of ERBB2 stimulation. Both the growth inhibition and
enhanced apoptosis were observed in wild-type TP53 cell lines
after ERBB2 transfection. In the same conditions, TP53 mutant
cells demonstrated enhanced growth (Casalini et al, 2001; Huang
et al, 2002). Huang et al (2002) concluded that TP53 defects ‘played
a permissive role in ERBB2 upregulation’, and ‘ERBB2 over-
expression phenotype might in turn select for the survival of cells
with p53 mutations’.
The common criteria of ERBB2 positivity (2þ and 3þ)i n
tumour tissues were established with reference to ERBB2 expres-
sion in normal tissues. It has been shown that ERBB2 is normally
expressed (1þ) on epithelial cell membranes including ovarian
epithelium and this is not due to gene amplification (Berchuck
et al, 1990; Press et al, 1990; Rubin et al, 1993). On the other hand,
Press et al (2002) evaluated CB11 expression (anti-ERBB2 antibody
approved by FDA for clinical testing) (Press et al, 1994; Felip et al,
1995; Van der Zee et al, 1995; Bookman et al, 2003) in tumours
with determined ERBB2 gene amplification and mRNA expression,
and found better CB11 sensitivity and accuracy for staining
categories 1þ to 3þ than for 2þ and 3þ alone; the specificity
was similar (98.6 vs 100%, respectively).
In the light of these findings, we aimed to evaluate the clinical
significance of ERBB2 expression in a large group of advanced
stage ovarian carcinomas, with the application of less stringent
criteria of ERBB2 overexpression, and with respect to TP53 status.
Another aim of the study was to test a novel CBE356 antibody
(against external epitope of ERBB2) and to find out whether the
evaluation of the internal (CB11) and external epitope of ERBB2
would be more clinically relevant than the evaluation of internal
epitope only.
MATERIALS AND METHODS
Patients and tumours
The study was performed on archival material from 233 ovarian
carcinoma patients operated on in the years 1987–1999. Medical
records were critically reviewed by at least two clinicians. The
material was carefully selected out of 548 cases submitted to meet
the following criteria: no chemotherapy before staging laparotomy,
adequate staging procedure, International Federation of Gyneco-
logists and Obstetricians stage IIB to IV disease (Creasman, 1989),
standard CP (cisplatin–cyclophosphamide or carboplatin–cyclo-
phosphamide) or CAP chemotherapy (CP with the addition of
doxorubicin), tumour tissue from the first laparotomy available,
Table 1 Selected studies on clinical significance of ERBB2 expression in ovarian cancer patients (with positive results, the type of analysis is given, and a
group in which the result has been found)
References
No. of
patients Antibodies
Criterion of positivity
Frequency of staining
CR or CR plus PR or
PS DFS OS
Berchuck et al (1990) 73 TA1 (3+)
32%
Po0.05
Fisher’s test
P¼0.001
univariate
Kacinski et al (1992) 72
a Anti-NEU Weak, strong
3.1%
NS NS
Rubin et al (1993) 105
a 9G6 (3+), 24% NS
Scambia et al (1993) 94
a Monoclonal pool Weak, strong
35%
NS NS
Meden et al (1994) 275 19% YES
multivariate
Fajac et al (1995) 52 Polyclonal (410%)
44%
NS
Felip et al (1995) 106
a CB11 (3+)
21.7%
P¼0.004
w
2 test
Po0.001
(FIGO III, IV)
multivariate
Van der Zee et al (1995) 89
a CB11 (45%)
20%
NS NS NS
Tanner et al (1996) 79
a mRNA Strong
20%
P¼0.04 (FIGO III, IV)
univariate
Meden et al (1998) 208
a Polyclonal, 9G6 45%
22%
P¼0.0003
univariate
Hengstler et al (1999) 77
a mRNA P¼0.036
multivariate
Ferrandina et al (2002) 76
a 300G9 (3+)
21%
NS NS
Present study 233
a CB11, 10A7 (1+, 2+, 3+)
42%
P¼0.022
(TP53 )
multivariate
P¼0.009
(TP53+)
multivariate
NS
DFS¼disease-free survival; CR¼complete remission; PR¼partial remission; PS¼platinum sensitivity; OS¼overall survival; NS¼not significant; no information on association
means that it was not studied.
aPlatinum-based chemotherapy.
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ymoderate (G2, 13%) or poor tumour differentiation (G3 and G4,
87%) and the availability of clinical data including residual tumour
(RT) size and follow-up observation (Table 2).
All tumours were uniformly reviewed histopathologically,
classified according to the criteria of the World Health Organisa-
tion (WHO) (Russell, 1994) and graded in a four-grade scale,
according to the criteria given by Broders (Barber et al, 1975).
There were 180 serous carcinomas (77%), 14 endometrioid (6%),
12 clear-cell type (5%), 14 undifferentiated (6%) and 13 other type
carcinomas (6%).
Follow-up time ranged from 1.44 to 168.8 months (median 26
months), and 189 patients (81%) have died. Response to
chemotherapy was determined retrospectively according to the
WHO criteria (Miller et al, 1981). The evaluation was based on
data from medical records describing the patient’s clinical
condition and CA125 levels in 3- to 4- week intervals. Complete
remission was defined as disappearance of all clinical and
biochemical symptoms of ovarian cancer evaluated after comple-
tion of first-line chemotherapy and confirmed at 4 weeks. Then,
the patients were followed in 1- (33%), 2- (26%) or 3-month
intervals (depending on the hospital centre) up to 6 or 12 months
after completion of the first line of chemotherapy, and further in
2- to 3-month intervals up to 2 years after completion of
chemotherapy. Within the CR group (N¼123), we have identified
a platinum-sensitive group (disease-free survival (DFS) longer
than 6 months, 101 patients) (Christian and Trimble, 1994). The
other tumours (partial remission – PR; progression – P; no change
– NC), as well as the CR group with DFS shorter than 6 months,
were described as resistant to cisplatin (Christian and Trimble,
1994) (Table 2) (Kupryjanczyk et al, 2003).
Immunohistochemical analysis
Immunohistochemical procedure was performed on paraffin-
embedded material after heat-induced epitope retrieval, according
to the description given previously (Kupryjanczyk et al, 2003). We
used CB11 (1:200) and the novel NCL-CBE356 (clone 10A7, 1:80,
further called CBE356) monoclonal antibodies (both from
Novocastra, Newcastle, UK) for the internal and external domains
of the ERBB2 receptor, respectively. For detection of the TP53
protein, we used PAb1801 monoclonal antibody (1:500, Sigma-
Genosys, Cambridge, UK) as described previously (Kupryjanczyk
et al, 2003).
Briefly, deparaffinised sections were boiled 3 5min (for
ERBB2) or 2 5min (for TP53) in a citrate buffer (pH 6.0) at
700W in a microwave. Nonspecific tissue and endogenous
peroxidase reactivity were blocked with 10% BSA and 3% H2O2,
respectively. Tissue sections were incubated with primary anti-
bodies overnight at 41C (for ERBB2) or for 1h (for TP53).
Biotinylated goat anti-mouse IgG (1:1500, cat. no. 816), perox-
idase-conjugated streptavidin (1:500, cat. no. 309) (both from
Immunotech, Marseille, France) and DAB were used as a detection
system. Cell lines, positive (SK-BR-3, MDA-175) and negative
(MDA-231) for ERBB2 protein, provided in the Dako Hercep-
Test
TM (cat. no. K 5204, Dako, Glostrup, Denmark) served as
controls for the procedure, as well as for the specificity of the
CBE356 antibody. As a positive control for TP53, we used a tumour
with a defined TP53 gene missense mutation (Kupryjanczyk et al,
2000). Normal mouse IgGs of the same subclasses and concentra-
tions as the primary antibodies served as negative controls, too.
Evaluation of immunohistochemical stainings
The semiquantitative evaluation of immunohistochemical stain-
ings was performed independently by two pathologists (JK, JB)
without the knowledge of clinical data, and a consensus was
reached in controversial cases. For the evaluation of ERBB2
expression, we applied the criteria approved by the US Food and
Drug Administration, that is, lack of membranous staining or
staining not exceeding 10% of cells was evaluated as negative;
weak, barely perceptible incomplete membranous staining in at
least 10% of cells was evaluated as 1þ; weak or moderate staining
in at least 10% of cells was evaluated as 2þ; and strong staining in
at least 10% of cells was evaluated as 3þ (Graziano, 1998; Jacobs
et al, 1999). Five tumours representative of each ERBB2 staining
category (in total 20) were stained once again for CBE356
expression 1 year after initial staining; the slides were evaluated
without knowledge of initial results and the results were
reproducible.
We combined CB11 expression with CBE356 expression
(CB11/CBE356 parameter) by taking the highest result obtained
with either antibody. For example, if a tumour was negative for
CB11 and 3þ positive for CBE356, CB11/CBE356 parameter was
scored 3þ.
TP53 protein accumulation was described as present (more than
10% of positive cells) or absent (Kupryjanczyk et al, 2003).
Statistical analysis
Associations between ERBB2 expression and clinicopathological
variables were analysed by w
2 test. Probablity of survival and DFS
were calculated using the Kaplan–Meier method (Kaplan and
Meier, 1958). Overall and DFS time analyses were performed with
multivariate Cox’s proportional hazards models (Cox, 1972).
Sensitivity to chemotherapy was evaluated with the multivariate
Table 2 Patient characteristics
N¼233
Age (years)
Range 24–77
Mean (s.d.) 53.2 (10.4)
FIGO stage
IIB+IIC 17 (7%)
IIIA+IIIB 54 (23%)
IIIC 132 (57%)
IV 30 (13%)
Residual tumour size
0 52 (22%)
40p2cm 60 (26%)
42cm 121 (52%)
Chemotherapy
CP 167 (72%)
CAP 66 (28%)
Response to chemotherapy
CR 123 (53%)
PR 36 (15%)
No change 8 (3%)
Progression 66 (28%)
Platinum sensitive 101 (43%)
Platinum resistant 132 (57%)
Recurrence rate in a CR group 98/123 (80%)
Outcome
NED 28 (12%)
AWD 16 (7%)
DOD 184 (79%)
DOC 5 (2%)
CP¼cyclophosphamide and cisplatin; CAP¼CP plus doxorubicin; CR¼complete
remission; NED¼no evidence of disease; AWD¼alive with disease; DOD¼died of
disease; DOC¼died of other causes.
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using the backward selection technique, where factors not
significant at 0.1 were drawn one by one out of the model. All
tests were two-sided and the level of significance was set at 5%.
The statistical analysis included the following independent
variables: age of patients, FIGO stage, RT size (0 vs p2cm, 0 vs
42cm), histological type and histological grade. We evaluated
clinical significance of CB11 expression, and that of CB11/CBE356
expression separately. The analysis was performed separately in
the TP53(þ) and TP53( ) subgroup, as well as in the whole
group. The latter analysis was performed to check whether the lack
of some ERBB2 associations in the TP53 subgroups was due to
lower group sizes.
RESULTS
CB11 and CBE356 expressions and their associations
Both antibodies gave membrane-bound (which is specific for
ERBB2 receptor) and cytoplasmic staining and the latter was not
taken into evaluation. Cytoplasmic staining for ERBB2 was usually
observed also by other authors (Felip et al, 1995; Van der Zee et al,
1995; Bookman et al, 2003). SK-BR-3 cell line (3þ) showed strong
complete membranous staining in the majority of cells with both
antibodies, and a variable cytoplasmic staining; MDA-175 cell line
(1þ) showed incomplete, barely perceptible membranous staining
in a small percentage of the cells with both antibodies, as well as
weak cytoplasmic staining in the Golgi region; MDA-231 cell line
(negative for ERBB2) did not show specific staining with either
antibody (Figure 1).
CB11 and CBE356 expressions were highly associated with each
other (Po0.00001); however, they did not completely overlap
(Table 3). CB11 expression was found in 54 tumours (23%, rates of
tumours with category 1þ,2 þ and 3þ were 7, 11 and 5%,
respectively); CBE356 expression was found in 79 tumours (34%, a
rate of tumours with category 1þ,2þ and 3þ was 13, 15.5 and
5.5%, respectively) (Figure 2). In all, 42% of the carcinomas
expressed either CB11 or CBE356 or both, and this is represented
by CB11/CBE356 parameter; for this parameter, the rates of
tumours with category 1þ,2 þ and 3þ were 15, 20 and 7%,
respectively. Thus, evaluation of both epitopes resulted in a much
higher percentage of positive tumours.
To determine biological and clinical significance of category
1þ staining, first we compared tumours with categories 0, 1þ
with those showing categories 2þ,3 þ, and then tumours with
category 0 with those showing categories 1þ to 3þ. Associations
between ERBB2 expressions and biological or clinical factors were
observed only if tumours with staining category 1þ were grouped
together with tumours showing staining categories 2þ and 3þ.
Thus, the term ‘ERBB2 or CB11 or CB11/CBE356 expression’ will
be further used in the meaning of staining categories 1þ to 3þ.
CB11 expression was more frequent in the TP53( ) than in the
TP53(þ) carcinomas (30 vs 18%, P¼0.04), as well as in FIGO IV
tumours than in other clinical stages (43% expressors in stage IV,
19% in stage IIIC, 20% in IIIA and B, 29% in IIB and C, P¼0.032).
CB11/CBE356 expression did not show such associations. CB11/
CBE356 expression was significantly less frequent in the serous
(37%) than in other types of carcinoma (58.5%) (P¼0.02). The
rate of strong CB11/CBE356 expression (category 2þ and 3þ)
was particularly low in the serous type (23 vs 43.5%, P¼0.01).
CB11 and CB11/CBE356 expressions were neither associated with
tumour differentiation nor with RT size.
Associations of ERBB2 expression with clinical end points
CB11/CBE356 parameter (1þ to 3þ) showed associations with
DFS and platinum sensitivity (PS), while CB11 expression alone
(1þ to 3þ) was associated with PS at the border of significance
only (Table 4). CB11/CBE356 expression enhanced 2.15 times the
risk of recurrence in the TP53(þ) group and not in the TP53( )
group (Figure 3). In the whole tumour group, the association and
the relative risk of recurrence were weaker than in the TP53(þ)
group (Table 4).
Figure 1 ERBB2 expression determined with NCL-CBE356 (10A7)
monoclonal antibody in the control cell lines: (A) negative MDA-231 cell
line, (B)1þ positive MDA-175 cell line and (C)3þ positive SK-BR-3 cell
line.
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CBE356 (clone 10A7) expression in 233 ovarian carcinomas
No. of tumours
Both stainings positive 35 (15%)
CB11 equal to 10A7 21
CB11 stronger than 10A7 8
CB11 weaker than 10A7 6
Both stainings negative 135 (58%)
One staining negative 63 (27%)
CB11 positive/ 10A7 negative 19
CB11 negative/10A7 positive 44
Figure 2 Strong membranous expression of ERBB2 in an ovarian
carcinoma (NCL-CBE356 antibody, clone 10A7, streptavidin–biotin–
peroxidase method, haematoxylin counterstain).
Table 4 Associations of ERBB2 expression with DFS (i.e. risk of recurrence, Cox’s proportional hazards model) and probability of PS (logistic regression
model) in the whole group of ovarian carcinomas, and in the TP53(+) and TP53( ) group
All patients, N¼233, 189 deaths TP53( ) group, N¼97, 80 deaths TP53(+) group, N¼136, 109 deaths
P-value P-value P-value
DFS CB11/CBE356
a 0.012 CB11/CBE356 0.009
RR¼1.71 RR¼2.15
95% CI (1.1, 2.6) 95% CI (1.2, 3.82)
CB11 0.07
FIGO IIIA, B 0.036 FIGO IIIA, B 0.43
FIGO IIIC o0.001 FIGO IIIC 0.001
FIGO IV o0.001 FIGO IV 0.002
PS CB11/CBE356 0.06 CB11/CBE356
OR¼0.33
95% CI (0.13, 0.85)
0.022
CB11
OR¼0.35
95% CI (0.12, 1.0)
0.05
RTp2cmvs 0 0.014 RTp2cmvs 0 0.03 RTp2cmvs 0 0.31
RT42cmvs 0 o0.001 RT42cmvs 0 0.001 RT42cmvs p2cm o0.001
aCB11/CBE356 and CB11 categories 1+, 2+ and 3+ were compared with category 0. When CB11/CBE356 and CB11 categories 2+ and 3+ were compared with category 0
and 1+, no associations have been found. FIGO stages depicted were compared with FIGO IIB and C; RR¼relative risk; OR¼odds ratio; DFS¼disease-free survival;
PS¼platinum sensitivity; CI¼confidence interval. Detailed statistical results of RT and FIGO stage analysis have been given in previous publications (Kupryjanczyk et al, 2003,
2004).
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Figure 3 Kaplan–Meier curves for DFS in the TP53( ) and TP53(þ)
subgroups in relation to ERBB2 expression.
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times) the probability of PS in the TP53( ) group, and not in the
larger TP53(þ) group. In the whole tumour group, CB11/CBE356
expression showed only a borderline association with PS. CB11
expression alone showed up as a factor influencing PS in the
TP53( ) group, while it was not associated with this end point in
the whole group (Table 4).
CB11/CBE356 expression showed weaker associations with DFS
or PS than clinical parameters. DFS was also associated with FIGO
stage in the TP53(þ) and in the whole group (lack of association
in the TP53( ) group may be due to lower group size, Table 4).
Residual tumour size (RT) was the only clinical parameter
associated with PS in this analysis. Interestingly, complete
debulking, when compared with RT p2cm, enhanced the
probability of platinum-sensitive response in the TP53( ) group,
while this has not been observed in the TP53(þ) group (Table 4).
Other factors evaluated did not show associations with DFS or PS.
Overall survival and CR were not associated with ERBB2
expression. For full and detailed analysis of clinical factors in this
patient group, the reader is referred to other publications
(Kupryjanczyk et al, 2003, 2004).
DISCUSSION
We have demonstrated the clinical significance of ERBB2
expression in ovarian carcinoma patients, that is, associations
with PS and DFS, using a novel approach to the analysis that
included: (1) evaluation in subgroups determined by TP53 status,
(2) broader criteria for ERBB2 positivity and (3) a combined end-
result from two monoclonal antibodies that identified the external
and internal domains of ERBB2.
In our study, TP53 protein accumulation determined the clinical
significance of ERBB2 expression. Platinum resistance related to
ERBB2 expression was observed in the TP53( ) group only.
Pegram et al (1997) reported that ERBB2 cDNA transfection into
breast and ovarian cancer cell lines differentially influenced their
sensitivity to cisplatin. We have confronted their findings with the
known TP53 status in some of those cell lines and the result is in
accord with our observations. MCF-7/HER-2 and 2008/HER-2 cells
that have wild-type TP53 showed resistance to cisplatin, while
MDA-MB-435/HER-2, MDA-MB-231/HER-2 and Caov3-HER-2,
which carry TP53 gene mutation, did not differ in this respect
from their progenitors without HER-2 expression; an exception is
BT-20/HER-2 cell line that accumulates TP53 protein and is more
resistant to cisplatin than parental cells without HER-2 expression
(Barboule et al, 1995; Pegram et al, 1997). Mutated TP53 most
frequently results in profound alterations such as loss of cell-cycle
control, impaired repair of DNA damage, apoptosis insufficiency
as well as genomic instability. Possibly, ERBB2 overexpression in
tumours with such molecular background is a minor additional
alteration in terms of cell response to chemotherapy.
Furthermore, in our study, ERBB2 expression carried higher risk
of recurrence (i.e. shorter DFS) in the TP53(þ) group only and
this may have an explanation in the findings of Casalini et al
(2001) and Huang et al (2002). Tumour recurrence depends on
cancer cell repopulation. Lincet et al (2000) reported that wild-type
TP53 prevented cell repopulation by induction of P21
WAF1. On the
other hand, Huang et al (2002) observed that ERBB2 expression in
wild-type TP53 MCF-7 cells induced TP53, P21
WAF1, C-MYC and
decreased BCL-2 expression (i.e. events promoting growth arrest
and apoptosis), while this has not been observed after transfection
of dominant-negative (i.e. mutant) TP53 (Casalini et al, 2001;
Huang et al, 2002).
Our results suggest that the currently applied criteria for ERBB2
overexpression in ovarian cancer (i.e. 2þ and 3þ) are too
restrictive and from the clinical viewpoint it would be justified to
include any ERBB2 membranous expression in above 10% of the
tumour cells to positivity (or overexpression). One explanation of
our findings might be that ERBB2 staining in paraffin-embedded
material is artefactually diminished as compared with frozen
tissue, and this is particularly true for weak and moderate
expression (Slamon et al, 1989; Press et al, 1994). Our rate of
42% of the ovarian carcinomas expressing ERBB2 is close to
43–44% reported by Kacinski et al (1992) and Fajac et al (1995),
who used similar criteria of positivity as in our study (Table 1).
A question related to this matter is whether tumours with weak
ERBB2 expression would respond to anti-ERBB2 therapy. In both
the clinical and the experimental studies on breast carcinomas, as
well as on some ovarian cancer cell lines, tumour response to
trastuzumab was proportional to the levels of ERBB2 expression
(Xu et al, 1999; Vogel et al, 2002). While cell lines with low ERBB2
expression did not respond to an antibody therapy, fortunately,
the antibody-mediated proliferation stimulation was not observed
either (Xu et al, 1999). It is possible that the biological and clinical
effect of anti-ERBB2 therapy in ovarian carcinoma cases with weak
or higher ERBB2 expression will become apparent, if this is
evaluated with respect to TP53 status.
Three immunohistochemical assays approved by FDA for
clinical testing, that is, HercepTest assay, CB11 and 4D5 (‘Clinical
Trials Assay’) and the Ventana Pathway CB11, as well as many
other anti-ERBB2 antibodies (about 30), have different sensitivity
and specificity when confronted with more objective methods of
evaluation of gene amplification or expression (Press et al 1994,
2002; Jacobs et al, 1999; Roche and Ingle, 1999). We have chosen
the known CB11 antibody against the internal domain, because it
is approved for clinical testing (Press et al, 1994; Felip et al, 1995;
Van der Zee et al, 1995; Bookman et al, 2003). We also wanted to
test the novel 10A7 (NCL-CBE356) antibody against the external
domain of ERBB2.
CB11 expression alone showed less clinical importance than the
end-result from the two antibodies. During revision of this paper,
for the purpose of discussion, we also checked whether CBE356/
10A7 expression alone associates with PS or DFS; however, it did
not show any clinical significance. Thus, it appears that
concomitant evaluation of expression of the internal and external
ERBB2 domains may be more clinically useful; possibly, similar
results could be obtained with other anti-ERBB2 antibodies.
With the methods applied, we have possibly identified
subgroups of ovarian cancer patients who may benefit from anti-
ERBB2 therapy, and timing of such a therapy. Our results could
suggest that trastuzumab should be given postoperatively to
patients with TP53( )/ERBB2(þ) ovarian carcinomas (in our
study 18%) to enhance PS; as shown above, postoperative
trastuzumab might be useless in patients with TP53(þ)/
ERBB2(þ) carcinomas because in the TP53(þ) group, ERBB2
expression does not diminish PS. However, trastuzumab should be
given to patients with TP53(þ)/ERBB2(þ) ovarian carcinomas
who reached CR, that is, after completion of chemotherapy (in our
study 12.4% of all patients), because in this group it might extend
DFS time. According to our results (lack of associations with
overall survival), the group of patients with TP53(þ)/ERBB2(þ)
tumours who did not reach CR would not qualify for trastuzumab
treatment. Thus, novel criteria for ovarian cancer patient inclusion
for clinical trials with trastuzumab should be considered and
further tested. If confirmed, our results could create a perspective
of the additional treatment for 30% of patients with advanced stage
ovarian carcinomas.
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